GSK’s Nucala Proves to be Superior than AZ’s Fasenra and Teva’s Cinqair for the Treatment of Severe Eosinophilic Asthma

 GSK’s Nucala Proves to be Superior than AZ’s Fasenra and Teva’s Cinqair for the Treatment of Severe Eosinophilic Asthma

GSK’s Nucala Proves to be Superior than AZ’s Fasenra and Teva’s Cinqair for the Treatment of Severe Eosinophilic Asthma

Shots:

  • The comparison study led to assessing of Nucala (mepolizumab), Fasenra (benralizumab), Cinqair (reslizumab) in patients aged ≥12 yrs with similar blood eosinophil counts for the treatment of severe eosinophilic asthma
  • Results: Nacula 100mg SC reduces clinically significant exacerbations (34% to 45% vs Fasenra 30mg) and (45% vs Cinqair 3mg/kg) in ≥400 cells/μL based on ACQ guidelines
  • Nacula is been evaluated in 3,000 patients in 16 clinical trials and approved in US, EU and in over 20 other markets. It is currently being evaluated for severe hypereosinophilic syndrome, nasal polyposis and COPD

Click here to read full press release/ article | Ref: GSK | Image: New Scientist

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post